[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337693-105":59,"doc-detail-337693-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","car-based-immunotherapy-for-breast-cancer-peculiarities-ongoing-investigations-and-future-strategies","CAR-based immunotherapy for breast cancer - peculiarities, ongoing investigations, and future strategies","","Breast cancer therapies including surgery, chemotherapy, and endocrine treatment have improved outcomes for Luminal A, Luminal B, and HER2-positive subtypes, yet triple-negative breast cancer (TNBC) remains difficult to treat. Rapid progress in chimeric antigen receptor (CAR)-T approaches for hematologic malignancies motivates CAR-based immunotherapy for breast cancer. This review summarizes effective and emerging CAR targets across subtypes, with emphasis on TNBC, and discusses challenges from the tumor microenvironment and CAR-T side effects. It also evaluates CAR macrophages, CAR-NK cells, CAR-MSCs, and CAR-expressing exosome strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/car-based-immunotherapy-for-breast-cancer-peculiarities-ongoing-investigations-and-future-strategies/337693/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/car-based-immunotherapy-for-breast-cancer-peculiarities-ongoing-investigations-and-future-strategies/337693.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is CAR-based immunotherapy important for breast cancer, especially TNBC?","Question",{"text":112,"@type":113},"Despite improved outcomes for Luminal A, Luminal B, and HER2-positive cancers, TNBC has limited effective treatment options and persistent risks of resistance and recurrence. CAR-based immunotherapy offers new strategies inspired by CAR-T success in hematological tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What factors are emphasized for selecting CAR targets in breast cancer?",{"text":117,"@type":113},"Choosing suitable and specific targets is crucial for applying CAR-T therapy effectively. The review summarizes both effective and potential targets across breast cancer subtypes, particularly for TNBC.",{"name":119,"@type":110,"acceptedAnswer":120},"What challenges limit CAR-based immunotherapy in solid tumors?",{"text":121,"@type":113},"Challenges include the tumor microenvironment of breast tumors and side effects of CAR-T therapy. These factors complicate effective and safe translation of CAR-based approaches.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337693,1790189324,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","TYPE Review  \nPUBLISHED 12 April 2024  \nDOI 10.3389/fimmu.2024.1385571  \nOPEN ACCESS  \nEDITED BY  \nHongru Zhang,  \nNankai University, China  \nREVIEWED BY Guoqiang Liu,  \nUniversity of Notre Dame, United States Fanying Tang,  \nNovartis, United States Guiling Wang,  \nChina Medical University, China Quanli Yang,  \nJinan University, China  \n*CORRESPONDENCE Yiming Yang  \n [ym_yang@jlu.edu.cn](ym_yang@jlu.edu.cn)  \nRECEIVED 13 February 2024  \nACCEPTED 27 March 2024  \nPUBLISHED 12 April 2024  \nCITATION  \nNiu Z, Wu J, Zhao Q, Zhang J, Zhang P and Yang Y (2024) CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.  \nFront. Immunol. 15:1385571 .  \ndoi: 10.3389/fimmu.2024.1385571  \nCOPYRIGHT  \n© 2024 Niu, Wu, Zhao, Zhang, Zhang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies  \nZhipu Niu 1, Jingyuan Wu 1, Qiancheng Zhao 2, Jinyu Zhang 3, Pengyu Zhang 1 and Yiming Yang 2*  \n1Clinical Medicine, China-Japan Union Hospital of Jilin University, Changchun, China, 2 Department of Cell Biology and Medical Genetics, College of Basic Medical Sciences, Jilin University,  \nChangchun, China, 3 Department of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, China  \nSurgery, chemotherapy, and endocrine therapy have improved the overall survival and postoperative recurrence rates of Luminal A, Luminal B, and HER2-positive breast cancers but treatment modalities for triple-negative breast cancer (TNBC) with poor prognosis remain limited. The effective application of the rapidly developing chimeric antigen receptor (CAR)-T cell therapy in hematological tumors provides new ideas for the treatment of breast cancer. Choosing suitable and speciﬁc targets is crucial for applying CAR-T therapy for breast cancer treatment. In this paper, we summarize CAR-T therapy ’s effective targets and potential targets in different subtypes based on the existing research progress, especially for TNBC. CAR-based immunotherapy has resulted in advancements in the treatment of breast cancer . CARmacrophages, CAR-NK cells, and CAR-mesenchymal stem cells (MSCs) may be more effective and safer for treating solid tumors, such as breast cancer. However, the tumor microenvironment (TME) of breast tumors and the side effects of CAR-T therapy pose challenges to CAR-based immunotherapy. CAR-T cells and CAR-NK cells-derived exosomes are advantageous in tumor therapy. Exosomes carrying CAR for breast cancer immunotherapy are of immense research value and may provide a treatment modality with good treatment effects. In this review, we provide an overview of the development and challenges of CAR-based immunotherapy in treating different subtypes of breast cancer and discuss the progress of CAR-expressing exosomes for breast cancer treatment. We elaborate on the development of CAR-T cells in TNBC therapy and the prospects of using CAR-macrophages, CAR-NK cells, and CARMSCs for treating breast cancer.  \nKEYWORDS  \nbreast cancer, CAR-T, CAR-NK, CAR-M, exosome, TME, TNBC  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nBreast cancer, the most common malignancy in women, is a developmental dysplasia of malignant cells of the ductal or lobular compartment of the breast (1) . According to global cancer statistics for 2020, breast cancer accounts for an estimated 11.7% of 19.3 million new cancer cases and 6 .9% of 10 million cancer deaths (2) . Based on the expression of estrogen r","cbCaivUESaDSBr84","https://ap.wps.com/l/cbCaivUESaDSBr84","pdf",1955955,"English","# Introduction\n## Breast cancer subtypes and clinical challenges\n## Rationale for CAR-based immunotherapy and CAR-T expansion","[{\"question\":\"Why is CAR-based immunotherapy important for breast cancer, especially TNBC?\",\"answer\":\"Despite improved outcomes for Luminal A, Luminal B, and HER2-positive cancers, TNBC has limited effective treatment options and persistent risks of resistance and recurrence. CAR-based immunotherapy offers new strategies inspired by CAR-T success in hematological tumors.\"},{\"question\":\"What factors are emphasized for selecting CAR targets in breast cancer?\",\"answer\":\"Choosing suitable and specific targets is crucial for applying CAR-T therapy effectively. The review summarizes both effective and potential targets across breast cancer subtypes, particularly for TNBC.\"},{\"question\":\"What challenges limit CAR-based immunotherapy in solid tumors?\",\"answer\":\"Challenges include the tumor microenvironment of breast tumors and side effects of CAR-T therapy. These factors complicate effective and safe translation of CAR-based approaches.\"}]","CAR-based immunotherapy for breast cancer - peculiarities, ongoing investigations, and future strategies | PDF",1790020183,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ce2d87bf94644dc302f172bec0c963a.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7bb44e76583a078d86611b59312a7ffe.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5261e2a19c81d86f4a4c2300bb3473a2.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84ded81f40f2eef4db6a8f52d1110233.webp",980,1385]